Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

Since my previous article, shares of Abbott Laboratories have returned 10 ... It's just not up to par with what I would need to see to maintain my buy rating. I would need to see a pullback to ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...

The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price target at $133.00. Larry Biegelsen has given his Buy rating ...

Citi reaffirmed its positive stance on Abbott Laboratories (NYSE:ABT), maintaining a Buy rating and a price target of $127.00. The endorsement follows updates from the company's management ...

Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the beginning of Abbott's immunodiagnostics business. A year later, the Abbott Diagnostics Division was ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s shares closed yesterday at $117.82. According to ...